Email Contact Phone Company Visit Website

Location Office

Kungsgatan 36
Stockholm
SE

NASDAQ OMX New York Head Office

One Liberty Plaza
New York
NY
US

NASDAQ OMX Stockholm Office

Tullvaktsvägen 15
Stockholm
SE

NASDAQ OMX Rockville Office

805 King Farm Boulevard 1st and 2nd floor
Rockville
MD
US

NASDAQ OMX London Office

Woolgate Exchange, 25 Basinghall Street, City of London
London
GB

NASDAQ OMX New York Office

Marketsite 4 Times Square
New York
NY
US

NASDAQ OMX Hong Kong Office

Room 1207-8, 12/F Man Yee Building 68 Des Voeux Road Central Hong Kong
Hong Kong
HK

NASDAQ OMX Singapore Office

20 Collyer Quay, #17-01
Singapore
SG

NASDAQ OMX Chicago Office

One North Wacker Drive Suite 3600
Chicago
IL
US

NASDAQ OMX Belgium Office

Avenue de Cortenbergh 116
Brussels
BE

NASDAQ OMX Dubai Office

Dubai World Trade Centre Sheikh Zayed Road
Dubai
AE

NASDAQ OMX Tokyo Office

1F, Kojimachi Square Building Nibancho, 3 Chiyoda-ku, Tokyo
Tokyo
JP

NASDAQ OMX Boston Office

100 Franklin St
Boston
MA
US

Location Office

Level 17-19, 110 Bishopsgate
London
GB

Telephone

212 231 5018

Contact

Todd A Swearingen
[email protected]
Back to all NASDAQ OMX announcements

NASDAQ OMX Welcomes Lidds to First North

NASDAQ OMX (NASDAQ: NDAQ) announces that the trading in LIDDS AB (LIDDS) shares commenced today on First North at NASDAQ OMX Stockholm. LIDDS belongs to the Health Care sector and is the 27th company to be admitted to trading on First North’s Nordic markets (Stockholm, Helsinki, Copenhagen and Iceland) in 2014.

LIDDS (Local Intelligent Drug Delivery System) is a Swedish pharmaceutical company developing innovative pharmaceutical products based on medical need and its proprietary drug delivery technology. LIDDS was initially founded by researchers and entrepreneurs at Uppsala University, departments of pharmacy and material sciences and University of Gothenburg, departments of urology and oncology, and within the life-science incubator P.U.L.S. AB. LIDDS is located in Helsingborg, Sweden, in one of Europe’s premiere biotechnology regions.   

Lars Åke Malmsten, CEO of LIDDS, commented: “With a successful IPO and listing on First North we can now proceed with the clinical development of our first product Liproca Depot intended for local treatment of prostate cancer and develop new applications of our proprietary drug delivery technology with a focus on localized cancer forms.”

“We welcome LIDDS to NASDAQ OMX First North and to our Health Care sector,” said Adam Kostyal, Senior Vice President at NASDAQ OMX. “It is our pleasure to see that LIDDS is one of many innovative life science companies that have opted for a listing at First North. We congratulate LIDDS on their successful initial public offering, and we look forward to supporting them in their continued journey as a publicly traded company.”

LIDDS has appointed Erik Penser Bankaktiebolag as Certified Adviser.